Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about CHUGAI PHARMACEUTICAL CO., LTD
2021CHUGAI PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
2021CHUGAI PHARMACEUTICAL : Signs Joint Research Agreement with NCC for Asian International Co..
PU
2021Launch of Chugai's New TV Commercial 'Protect the Ordinary Days People Cherish' Featuri..
AQ
2021CHUGAI PHARMACEUTICAL : Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indi..
PU
2021CHUGAI PHARMACEUTICAL : Launch of Chugai's New TV Commercial “Protect the Ordinary D..
PU
2021Chugai Pharmaceutical Co., Ltd. - Notice of Board of Director's Resolution on Applicati..
AQ
2021Chugai Obtained Highest A-Rating by CDP in Two Categories and SBT Validation for Greenh..
AQ
2021Chugai Pharmaceutical Co. - Update on the Development of Oral COVID-19 Drug Candidate A..
AQ
2021Nikkei 225 Declines 1.8% on Central Bank Outlooks
MT
2021CHUGAI PHARMACEUTICAL : Notice of Board of Director's Resolution on Application for New Ma..
PU
2021CHUGAI PHARMACEUTICAL : Obtained Highest A-Rating by CDP in Two Categories and SBT Validat..
PU
2021CHUGAI PHARMACEUTICAL : In-Licenses Gene Therapy Delandistrogene Moxeparvovec (SRP-9001) f..
PU
2021CHUGAI PHARMACEUTICAL : Update on the Development of Oral COVID-19 Drug Candidate AT-527 i..
PU
2021Interim Data from Phase III HAVEN 6 Study Demonstrate Safety and Efficacy Profile of Ch..
AQ
2021Interim data from phase III HAVEN 6 study demonstrate favourable safety and efficacy pr..
AQ
2021CHUGAI PHARMACEUTICAL : Files for Additional Indication of Actemra for COVID-19 Pneumonia ..
PU
2021CHUGAI PHARMACEUTICAL : Interim Data from Phase III HAVEN 6 Study Demonstrate Safety and E..
PU
2021Interim data from phase III HAVEN 6 study demonstrate favourable safety and efficacy pr..
AQ
2021CHUGAI PHARMACEUTICAL : Files for Additional Indication of Polivy for Previously Untreated..
PU
2021Chugai's Actemra, RoActemra Approved by the European Commission to Treat Patients with ..
AQ
2021Nikkei 225 Gains 1.4% on Fading Omicron Concerns
MT
2021CHMP Recommends EU Approval of Chugai's Actemra, RoActemra to Treat Patients with Sever..
AQ
2021CHUGAI PHARMACEUTICAL : Actemra/RoActemra Approved by the European Commission to Treat Pat..
PU
2021CHUGAI PHARMACEUTICAL : CHMP Recommends EU Approval of Chugai's Actemra/RoActemra to Treat..
PU
2021Chugai - Towa Pharmaceutical Receives Approval for Authorized Generic Version of Chugai..
AQ
2021CHUGAI PHARMACEUTICAL : Towa Pharmaceutical Receives Approval for Authorized Generic Versi..
PU
2021Chugai Launches a New Educational Website 'So-Zo LABO' Aiming for a Society that Embrac..
AQ
2021CHUGAI PHARMACEUTICAL : Launches a New Educational Website “So-Zo LABO” Aiming..
PU
2021Chugai Pharmaceutical Co. - Anti Cancer Agent Herceptin Approved for Additional Indicat..
AQ
2021CHUGAI PHARMACEUTICAL : Anti-Cancer Agent Herceptin Approved for Additional Indication of ..
PU
2021Beijing IP Court To Hear China's First Case Of Patent Linkage
AQ
2021CHUGAI PHARMACEUTICAL : Personnel Changes
PU
2021CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
2021CHUGAI PHARMACEUTICAL : Atea Announces Update on Collaboration with Roche for AT-527
PU
2021Chugai Continuously Selected in the 'DJSI World,' a Global ESG Investment Index
AQ
2021CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for FoundationOne CDx Cancer Genomic P..
PU
2021CHUGAI PHARMACEUTICAL : Hosted Discussion Series to Drive Quality Cancer Care in Developin..
PU
2021CHUGAI PHARMACEUTICAL : Continuously Selected in the “DJSI World,” a Global ES..
PU
2021TIMELINE : Toshiba's lurch from crisis to crisis since 2015
RE
2021Atea Announces Update of Clinical Studies Evaluating AT-527 for COVID-19 in the Outpati..
PU
2021TIMELINE-Toshiba's lurch from crisis to crisis since 2015
RE
2021Chugai Files for Additional Indication of Hemlibra for Treatment of Acquired Hemophilia..
PU
2021Chugai Pharmaceutical - The Antibody Cocktail, Ronapreve Approved for Additional Indica..
AQ
2021Japan stocks end lower as dour earnings hit construction firms
RE
2021The Antibody Cocktail, Ronapreve Approved for Additional Indication as a Preventive Tre..
PU
2021Japan health ministry panel approves expanded use of Chugai's COVID-19 antibody treatme..
RE
2021Chugai Pharmaceutical - Completion of Enrollment in Phase III Comparative Study for Inv..
AQ
2021Completion of Enrollment in Phase III Comparative Study for Investigational Regenerativ..
PU
2021CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
2021CHUGAI PHARMACEUTICAL : Announces 2021 3rd Quarter Results
AQ
2021CHUGAI PHARMACEUTICAL : Notice of Revisions to Financial Forecasts
AQ
2021CHUGAI PHARMACEUTICAL : Notice of Revisions to Dividend Forecast for Fiscal Year Ending De..
AQ
2021CHUGAI PHARMACEUTICAL : Construction of New Bio API Plant for Early Clinical Trials to Acc..
AQ
2021CHUGAI PHARMACEUTICAL : announced Organizational Changes
AQ
2021CHUGAI PHARMACEUTICAL : Posts 26% Growth in Nine-Month Attributable Net Income, Raises FY2..
MT
2021Nikkei 225 Slips 0.7% on Earnings, Election Outlooks
MT
2021Nikkei slips on soft earnings, U.S. tech worries
RE
2021Nikkei drops on soft earnings, U.S. tech worries
RE
2021CHUGAI PHARMACEUTICAL : Organizational Changes
PU
2021CHUGAI PHARMACEUTICAL : Announces 2021 3rd Quarter Results
PU
2021CHUGAI PHARMACEUTICAL : Notice of Revisions to Financial Forecasts
PU
2021CHUGAI PHARMACEUTICAL : Notice of Revisions to Dividend Forecast for Fiscal Year Ending De..
PU
2021CHUGAI PHARMACEUTICAL : Construction of New Bio API Plant for Early Clinical Trials to Acc..
PU
2021CHUGAI PHARMACEUTICAL : 3Q Results (Jan-Sep 2021)
PU
2021CHUGAI PHARMACEUTICAL : Supplementary Materials
PU
2021CHUGAI PHARMACEUTICAL : Supplementary Materials for Consolidated Financial Results for the..
PU
2021CHUGAI PHARMACEUTICAL : CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited)(for the thi..
PU
2021Chugai Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the Year End..
CI
2021CHUGAI PHARMACEUTICAL : Contribution of Para-transit Vehicles to Welfare Services
AQ
2021ROCHE : Chugai Pharmaceutical Co., Ltd. - F. Hoffmann-La Roche Announces Third Quarter Sal..
AQ
2021Chugai Pharmaceutical, Oncolys BioPharma to Nix Oncolytic Viral Immunotherapy License D..
MT
2021CHUGAI PHARMACEUTICAL : Contribution of Para-transit Vehicles to Welfare Services
PU
2021CHUGAI PHARMACEUTICAL : F. Hoffmann-La Roche Announces Third Quarter Sales 2021
PU
2021CHUGAI PHARMACEUTICAL : Atea Announces Update and Topline Results of MOONSONG Study Evalua..
PU
2021CHUGAI PHARMACEUTICAL : Announces the Decision of the Termination of Exclusive License Agr..
PU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on CHUGAI PHARMACEUTICAL CO., LTD
02/03/22
Upcoming sector events